Finance & economics | Free exchange

What performance-enhancing stimulants mean for economic growth

Could America’s Adderall shortage have harmed its productivity?

Towards the end of last year America began running short of medicines used to treat attention-deficit hyperactivity disorder (adhd), including Adderall (an amphetamine) and Ritalin (a central-nervous-system stimulant). Nine in ten pharmacies reported shortages of the medication, which tens of millions of Americans use to help improve focus and concentration. Around the same time, something intriguing happened: American productivity, a measure of efficiency at work, dropped. In the first quarter of 2023, output per hour fell by 3%.

This article appeared in the Finance & economics section of the print edition under the headline “Buzzkill”

From the May 27th 2023 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Finance & economics

A white fish going into the ,outh of a group of black fishes forming a bigger fish.

Why your portfolio is less diversified than you might think

The most important idea in modern finance has become maddeningly hard to implement

A German flag waves in front of the buildings of the banking district in Frankfurt, Germany.

Can Germany’s economy stage an unexpected recovery?

The situation is dire, but there are glimmers of hope


Italy's Prime Minister Giorgia Meloni smiles at the Palazzo Chigi in Rome.

Giorgia Meloni has grand banking ambitions

Will Italy’s nationalist prime minister manage to concentrate financial power?


Tech tycoons have got the economics of AI wrong

Following DeepSeek’s breakthrough, the Jevons paradox provides less comfort than they imagine

Donald Trump’s economic warfare has a new front

The president has threatened to blow up the global tax system. Will allies be able to stop him?

Don’t let Donald Trump see our Big Mac index

America’s tariff-loving president could learn the wrong lessons from international burger prices